SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD FEB 05
MCX SILVER MAR 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD FEB 05
MCX SILVER MAR 05
MCX CRUDEOIL FEB 19
MCX NATURALGAS JAN 25
USD/INR
EUR/INR
GBP/INR
JPY/INR

Sensex ends 746 points lower, Nifty down 1.5%; banking

Global Markets: Asia shares pare losses as China economy rebounds

Oil prices extend gains after US inventory drop

Wrapping 2020 with a subtle depreciation- What’s on the cards for the Rupee in 2021?

Healthcare

Serum says 'Covishield' safe and immunogenic; clarifies volunteer’s illness not due to vaccine

Updated : December 01, 2020 08:29 PM IST

The vaccine manufacturer clarified that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly.

Serum assured that the vaccine won’t be released for mass use unless it is proven immunogenic, and safe.

Amid concerns over the adverse event that was reported by a volunteer who participated in Serum Institute's vaccine trial, the company has issued a statement saying that ‘Covishield’ is safe and immunogenic.

"The incident with the Chennai volunteer though highly unfortunate was in no way induced by the vaccine and Serum Institute of India is sympathetic with the volunteer's medical condition," said Serum Institute in a statement issued on Tuesday.

The vaccine manufacturer clarified that all the requisite regulatory and ethical processes and guidelines were followed diligently and strictly.

"The concerned authorities were informed and the Principal Investigator, DSMB and the Ethics Committee independently cleared and reckoned it as a non-related issue to the vaccine trial. Post which we submitted all the reports and data related to the incident to the DCGI. It is only after we cleared all the required processes that we continued with the trials," stated the firm.

Serum assured that the vaccine won’t be released for mass use unless it is proven immunogenic, and safe. "Taking into consideration the complexities and existing misnomers about vaccination and immunization, the legal notice was sent therefore to safeguard the reputation of the company which is being unfairly maligned," it said.

Raising serious concerns on the safety and transparency of 'Covishield' clinical trials, the participant has demanded a Rs 5 crore compensation on charges that after getting the vaccine shot, he experienced a neurological breakdown and an inability to get back to normal life.

The volunteer had participated in phase 3 clinical trials and has claimed the vaccine is “not safe” and that the testing, manufacture and distribution of the vaccine should be stopped.

Serum Institute, in turn, had threatened to seek damages in excess of Rs 100 crore from the volunteer.

You May Also Like

GoAir offers 1 million seats at Rs 859 each on domestic travel

GoAir offers 1 million seats at Rs 859 each on domestic travel

PNB raises Rs 495 crore via AT-1 bonds

PNB raises Rs 495 crore via AT-1 bonds

Reliance Industries Q3 net profit up 40% to Rs 14,894 crore; revenue at Rs 1.23 lakh crore

Reliance Industries Q3 net profit up 40% to Rs 14,894 crore; revenue at Rs 1.23 lakh crore

Trending on CNBC-TV18

Live TV

recommended for you